Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Healthcare Sector — Last 30 Days

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume
Mar 26, 2026
Sale
Shares
159
Price
$530.95
Total Value
$84.42K
Shares Held After
49,854
% of Holdings
0.3%

BECTON DICKINSON & CO (BDX)

Feld Michael — EVP, Chief Revenue Officer
Mar 26, 2026
Sale
Shares
75
Price
$156.83
Total Value
$11.76K
Shares Held After
21,233
% of Holdings
0.4%

Neuronetics, Inc. (STIM)

Chernett Jorey — 10% Owner
Mar 26, 2026
Purchase
Shares
25,000
Price
$1.44
Total Value
$36.00K
Shares Held After
8,893,276
% of Holdings
0.3%
Mar 26, 2026
Sale
Shares
280
Price
$57.17
Total Value
$16.01K
Shares Held After
52,200
% of Holdings
0.5%
Mar 26, 2026
Sale
Shares
6,760
Price
$56.79
Total Value
$383.87K
Shares Held After
52,480
% of Holdings
11.4%

Centessa Pharmaceuticals plc (CNTA)

Weinhoff Gregory M — Chief Business Officer
Mar 26, 2026
Sale
Shares
23,998
Price
$30.00
Total Value
$719.94K
Shares Held After
65,925
% of Holdings
26.7%

ACADIA PHARMACEUTICALS INC (ACAD)

Kihara James — PRINCIPAL ACCOUNTING OFFICER
Mar 26, 2026
Sale
Shares
12
Price
$21.73
Total Value
$260.70
Shares Held After
26,885
% of Holdings
0.0%

ACADIA PHARMACEUTICALS INC (ACAD)

Kihara James — PRINCIPAL ACCOUNTING OFFICER
Mar 26, 2026
Sale
Shares
1,097
Price
$21.65
Total Value
$23.75K
Shares Held After
26,897
% of Holdings
3.9%

ACADIA PHARMACEUTICALS INC (ACAD)

Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER
Mar 26, 2026
Sale
Shares
37
Price
$21.72
Total Value
$803.54
Shares Held After
60,269
% of Holdings
0.1%

ACADIA PHARMACEUTICALS INC (ACAD)

Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER
Mar 26, 2026
Sale
Shares
3,171
Price
$21.65
Total Value
$68.65K
Shares Held After
60,306
% of Holdings
5.0%
Mar 26, 2026
Sale
Shares
19,060
Price
$14.12
Total Value
$269.13K
Shares Held After
468,892
% of Holdings
3.9%

Clene Inc. (CLNN)

Ugwumba Chidozie — 10% Owner
Mar 26, 2026
Sale
Shares
5,319
Price
$5.40
Total Value
$28.72K
Shares Held After
532,091
% of Holdings
1.0%
Mar 26, 2026
Sale
Shares
311
Price
$540.17
Total Value
$167.99K
Shares Held After
8,480
% of Holdings
3.5%
Mar 26, 2026
Sale
Shares
1,414
Price
$539.25
Total Value
$762.49K
Shares Held After
8,791
% of Holdings
13.9%
Mar 26, 2026
Sale
Shares
275
Price
$537.62
Total Value
$147.85K
Shares Held After
10,205
% of Holdings
2.6%

IMPACT BIOMEDICAL INC. (IBO)

Macko Todd D — Chief Financial Officer
Mar 25, 2026
Sale
Shares
1,600
Price
$0.60
Total Value
$961.28
Shares Held After
198,122
% of Holdings
0.8%
Shares
3,575
Price
$60.08
Total Value
$214.77K
Shares Held After
1,220,004
% of Holdings
0.3%

GLAUKOS Corp (GKOS)

Thurman Alex R. — SVP & CHIEF FINANCIAL OFFICER
Mar 25, 2026
Sale
Shares
2,511
Price
$106.46
Total Value
$267.32K
Shares Held After
41,967
% of Holdings
5.6%

Apogee Therapeutics, Inc. (APGE)

Henderson Jane — Chief Financial Officer
Mar 25, 2026
Sale
Shares
2,000
Price
$85.00
Total Value
$170.00K
Shares Held After
179,371
% of Holdings
1.1%
Shares
160
Price
$17.53
Total Value
$2.80K
Shares Held After
5,129,340
% of Holdings
0.0%
Shares
174,485
Price
$16.95
Total Value
$2.96M
Shares Held After
5,129,500
% of Holdings
3.3%

Enliven Therapeutics, Inc. (ELVN)

Collins Helen Louise — CHIEF MEDICAL OFFICER
Mar 25, 2026
Sale
Shares
40,000
Price
$35.10
Total Value
$1.40M
Shares Held After
25,000
% of Holdings
61.5%
Mar 25, 2026
Sale
Shares
14,295
Price
$36.97
Total Value
$528.51K
Shares Held After
28,231
% of Holdings
33.6%

Phreesia, Inc. (PHR)

Gandhi Balaji — Chief Financial Officer
Mar 25, 2026
Sale
Shares
3,829
Price
$11.26
Total Value
$43.13K
Shares Held After
146,740
% of Holdings
2.5%
Mar 25, 2026
Sale
Shares
26,198
Price
$50.07
Total Value
$1.31M
Shares Held After
2,918,326
% of Holdings
0.9%

Legend Biotech Corp (LEGN)

Huang Ying — Director
Mar 25, 2026
Sale
Shares
9,936
Price
$8.77
Total Value
$87.14K
Shares Held After
247,438
% of Holdings
3.9%

Neuronetics, Inc. (STIM)

Chernett Jorey — 10% Owner
Mar 25, 2026
Purchase
Shares
125,000
Price
$1.40
Total Value
$175.00K
Shares Held After
8,868,276
% of Holdings
1.4%
Mar 25, 2026
Sale
Shares
552
Price
$56.86
Total Value
$31.39K
Shares Held After
59,240
% of Holdings
0.9%
Mar 25, 2026
Sale
Shares
4,916
Price
$56.00
Total Value
$275.32K
Shares Held After
59,792
% of Holdings
7.6%
Mar 25, 2026
Sale
Shares
1,572
Price
$55.28
Total Value
$86.90K
Shares Held After
64,708
% of Holdings
2.4%

ACADIA PHARMACEUTICALS INC (ACAD)

Kihara James — PRINCIPAL ACCOUNTING OFFICER
Mar 25, 2026
Sale
Shares
833
Price
$21.47
Total Value
$17.88K
Shares Held After
25,852
% of Holdings
3.1%

ACADIA PHARMACEUTICALS INC (ACAD)

Rhodes Jennifer J — EVP, CHIEF LEGAL OFFICER, SEC
Mar 25, 2026
Sale
Shares
3,844
Price
$21.47
Total Value
$82.53K
Shares Held After
11,280
% of Holdings
25.4%

ACADIA PHARMACEUTICALS INC (ACAD)

Thompson Elizabeth H.Z. — EVP, Head of Research & Dev
Mar 25, 2026
Sale
Shares
3,435
Price
$21.47
Total Value
$73.75K
Shares Held After
3,280
% of Holdings
51.2%
Mar 25, 2026
Sale
Shares
11,641
Price
$21.47
Total Value
$249.93K
Shares Held After
14,803
% of Holdings
44.0%

ACADIA PHARMACEUTICALS INC (ACAD)

Schneyer Mark C. — EVP, CHIEF FINANCIAL OFFICER
Mar 25, 2026
Sale
Shares
4,177
Price
$21.47
Total Value
$89.68K
Shares Held After
57,299
% of Holdings
6.8%

Revolution Medicines, Inc. (RVMD)

Mancini Anthony — Chief Global Commercialization Officer
Mar 25, 2026
Sale
Shares
400
Price
$97.21
Total Value
$38.88K
Shares Held After
54,400
% of Holdings
0.7%

Revolution Medicines, Inc. (RVMD)

Mancini Anthony — Chief Global Commercialization Officer
Mar 25, 2026
Sale
Shares
11,036
Price
$96.43
Total Value
$1.06M
Shares Held After
54,800
% of Holdings
16.8%

Revolution Medicines, Inc. (RVMD)

Mancini Anthony — Chief Global Commercialization Officer
Mar 25, 2026
Sale
Shares
21,086
Price
$95.49
Total Value
$2.01M
Shares Held After
65,836
% of Holdings
24.3%

Revolution Medicines, Inc. (RVMD)

Mancini Anthony — Chief Global Commercialization Officer
Mar 25, 2026
Sale
Shares
3,128
Price
$94.16
Total Value
$294.52K
Shares Held After
86,922
% of Holdings
3.5%

Revolution Medicines, Inc. (RVMD)

Mancini Anthony — Chief Global Commercialization Officer
Mar 25, 2026
Sale
Shares
1,800
Price
$93.22
Total Value
$167.80K
Shares Held After
90,050
% of Holdings
2.0%

BioCardia, Inc. (BCDA)

Altman Peter — Director
Mar 25, 2026
Purchase
Shares
300
Price
$1.22
Total Value
$366.00
Shares Held After
274,766
% of Holdings
0.1%
Mar 25, 2026
Sale
Shares
19,060
Price
$14.27
Total Value
$271.99K
Shares Held After
473,230
% of Holdings
3.9%

Bicara Therapeutics Inc. (BCAX)

Raben David — Chief Medical Officer
Mar 25, 2026
Sale
Shares
5,500
Price
$18.95
Total Value
$104.23K
Shares Held After
55,286
% of Holdings
9.0%

Definium Therapeutics, Inc. (DFTX)

Sullivan Mark — Chief Legal Officer
Mar 25, 2026
Sale
Shares
10,702
Price
$18.47
Total Value
$197.67K
Shares Held After
271,079
% of Holdings
3.8%
Mar 25, 2026
Sale
Shares
24,431
Price
$18.47
Total Value
$451.24K
Shares Held After
752,454
% of Holdings
3.1%

Definium Therapeutics, Inc. (DFTX)

Karlin Daniel — Chief Medical Officer
Mar 25, 2026
Sale
Shares
8,018
Price
$18.47
Total Value
$148.09K
Shares Held After
413,317
% of Holdings
1.9%

Clene Inc. (CLNN)

Ugwumba Chidozie — 10% Owner
Mar 25, 2026
Sale
Shares
7,098
Price
$5.50
Total Value
$39.04K
Shares Held After
537,410
% of Holdings
1.3%

GENELUX Corp (GNLX)

Smalling Ralph — Head of Regulatory
Mar 25, 2026
Sale
Shares
240
Price
$2.51
Total Value
$602.40
Shares Held After
68,073
% of Holdings
0.4%

Nuvalent, Inc. (NUVL)

Balcom Alexandra — Chief Financial Officer
Mar 25, 2026
Sale
Shares
13,700
Price
$100.16
Total Value
$1.37M
Shares Held After
85,533
% of Holdings
13.8%

Rapport Therapeutics, Inc. (RAPP)

Yeleswaram Krishnaswamy — Chief Development Officer
Mar 25, 2026
Sale
Shares
10,115
Price
$29.99
Total Value
$303.35K
Shares Held After
286,876
% of Holdings
3.4%
Version: v26.3.33